197 related articles for article (PubMed ID: 1643153)
1. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications.
Hallek M; Wanders L; Strohmeyer S; Emmerich B
Ann Hematol; 1992 Jul; 65(1):1-5. PubMed ID: 1643153
[TBL] [Abstract][Full Text] [Related]
2. Serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma.
Madewell BR
J Vet Intern Med; 2004; 18(5):595-6. PubMed ID: 15515571
[TBL] [Abstract][Full Text] [Related]
3. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine.
Di Raimondo F; Giustolisi R; Lerner S; Cacciola E; O'Brien S; Kantarjian H; Keating MJ
Ann Oncol; 2001 May; 12(5):621-5. PubMed ID: 11432619
[TBL] [Abstract][Full Text] [Related]
4. Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients.
Broët P; Romain S; Daver A; Ricolleau G; Quillien V; Rallet A; Asselain B; Martin PM; Spyratos F
J Clin Oncol; 2001 Jun; 19(11):2778-87. PubMed ID: 11387348
[TBL] [Abstract][Full Text] [Related]
5. Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.
Rehn S; Gronowitz JS; Källander C; Sundström C; Glimelius B
Br J Cancer; 1995 May; 71(5):1099-105. PubMed ID: 7734308
[TBL] [Abstract][Full Text] [Related]
6. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.
Kok M; Bonfrer JM; Korse CM; de Jong D; Kersten MJ
Tumour Biol; 2003; 24(1):53-60. PubMed ID: 12743427
[TBL] [Abstract][Full Text] [Related]
7. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma.
He E; Xu XH; Guan H; Chen Y; Chen ZH; Pan ZL; Tang LL; Hu GZ; Li Y; Zhang M; Zhou J; Eriksson S; Fornander T; Skog S
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):352-8. PubMed ID: 20544519
[TBL] [Abstract][Full Text] [Related]
8. Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients.
Bogni A; Cortinois A; Grasselli G; Seregni E; Crippa F; Castellani MR; Bombardieri E
J Biol Regul Homeost Agents; 1994; 8(4):121-5. PubMed ID: 7660854
[TBL] [Abstract][Full Text] [Related]
9. Multienzymatic analyses of human malignant lymphomas. Correlation of enzymatic data with pathologic and ultrastructural findings in Burkitt's and lymphoblastic lymphomas.
Vezzoni P; Giardini R; Lombardi L; Rilke F; Lucchini R; Vezzoni MA; Clerici L
Cancer; 1984 Aug; 54(3):489-99. PubMed ID: 6428736
[TBL] [Abstract][Full Text] [Related]
10. Thymidine kinases: the enzymes and their clinical usefulness.
Hannigan BM; Barnett YA; Armstrong DB; McKelvey-Martin VJ; McKenna PG
Cancer Biother; 1993; 8(3):189-97. PubMed ID: 7804359
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of plasma levels of thymidine kinase and mutated p53 in 81 patients with newly diagnosed malignant lymphoma.
Lehtinen T; Aine R; Kellokumpu-Lehtinen P; Hakala T; Lehtinen M
Acta Oncol; 1993; 32(7-8):779-81. PubMed ID: 8305226
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia.
Musto P; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G; Modoni S; Parlatore L; Valvano MR; Carotenuto M
Br J Haematol; 1995 May; 90(1):125-30. PubMed ID: 7786774
[TBL] [Abstract][Full Text] [Related]
13. Thymidine kinase and thymidine phosphorylase activities in various types of leukaemia and lymphoma.
Vertongen F; Fondu P; van den Heule B; Cauchie C; Mandelbaum IM
Tumour Biol; 1984; 5(6):303-11. PubMed ID: 6536100
[TBL] [Abstract][Full Text] [Related]
14. Serum thymidine kinase as a prognostic marker in Hodgkin's disease.
Eriksson B; Hagberg H; Glimelius B; Sundström C; Gronowitz S; Källander C
Acta Radiol Oncol; 1985; 24(2):167-71. PubMed ID: 2988280
[TBL] [Abstract][Full Text] [Related]
15. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.
Hallek M; Emmerich B; Strohmeyer S; Busch R; Reichle A; Senekowitsch R
Klin Wochenschr; 1988 Aug; 66(16):718-23. PubMed ID: 3172680
[TBL] [Abstract][Full Text] [Related]
16. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer.
Romain S; Christensen IJ; Chinot O; Balslev I; Rose C; Martin PM; Thorpe SM
Int J Cancer; 1995 Mar; 61(1):7-12. PubMed ID: 7705935
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia.
Hallek M; Langenmayer I; Nerl C; Knauf W; Dietzfelbinger H; Adorf D; Ostwald M; Busch R; Kuhn-Hallek I; Thiel E; Emmerich B
Blood; 1999 Mar; 93(5):1732-7. PubMed ID: 10029603
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma.
Niitsu N; Okabe-Kado J; Kasukabe T; Yamamoto-Yamaguchi Y; Umeda M; Honma Y
Blood; 1999 Nov; 94(10):3541-50. PubMed ID: 10552965
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Hagberg H; Kalkner KM; Jalkanen S
Int J Cancer; 1998 Jun; 79(3):221-5. PubMed ID: 9645341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
